logo
Search orAI Icon𝛼SK
ENTITY
SMARTSCORE: 3.8/5
Astellas Pharma

Astellas Pharma (4503 JP)

178
Analysis
Health Care • Japan
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience and DM Complications and Metabolic Diseases. With over 17,000 global employees, Astellas researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia
more
bullish•MSCI ACWI Index
•14 Jun 2018 12:25

Global Equity Markets Overview

Over the past several weeks we have outlined the case for our increasingly bullish outlook, noting that market internals remain favorable and...

Logo
Vermilion Research
280 Views
Share
bullish•MSCI ACWI Index
•24 May 2018 12:43

Global Strategy: Opportunities in Health Care & Materials Stocks

Price and relative strength trends continue to improve for our international equal-weight Health Care Sector.We recommend adding exposure, and...

Logo
Vermilion Research
320 Views
Share
bullish•Astellas Pharma
•24 May 2018 11:29

Astellas Mid-Term Plan FY18-FY20e: Concerns Remain Over Growth Post-Xtandi LOE

Astellas Pharma Inc (4503 JP) announced it FY18-20e mid-term plan on May 22, 2018 While our FY20e sales estimates are in-line with the company...

Logo
Share
bullish•Astellas Pharma
•04 May 2018 14:39

Astellas FY17 Results and FY18e Guidance – No Major Surprise

Astellas Pharma Inc (4503 JP) FY17 results Xtandi (up 17% to ¥295b) and mirabegron (up 28% to ¥126b) ramp-up compensate for lackluster domestic...

Logo
Share
bullish•Thematic (Sector/Industry)
•24 Apr 2018 14:17

Japan Pharma - FY17e Earnings Preview (I)

Astellas Pharma Inc (4503 JP) - April 26, 2018FY18e potential guidance  Moderate Xtandi and Tarceva growth and Vesicare US patent expiry led y-o-y...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.59.2

x